Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Tax Provisions (2020 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Tax Provisions for 6 consecutive years, with -$30000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions fell 300.0% year-over-year to -$30000.0, compared with a TTM value of $299000.0 through Sep 2025, up 251.76%, and an annual FY2024 reading of $310000.0, up 297.44% over the prior year.
  • Tax Provisions was -$30000.0 for Q3 2025 at X4 Pharmaceuticals, down from $37000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $258000.0 in Q4 2024 and bottomed at -$30000.0 in Q3 2025.
  • Average Tax Provisions over 5 years is $24947.4, with a median of $15000.0 recorded in 2023.
  • The sharpest move saw Tax Provisions tumbled 750.0% in 2022, then soared 681.82% in 2024.
  • Year by year, Tax Provisions stood at $3000.0 in 2021, then soared by 366.67% to $14000.0 in 2022, then skyrocketed by 135.71% to $33000.0 in 2023, then skyrocketed by 681.82% to $258000.0 in 2024, then tumbled by 111.63% to -$30000.0 in 2025.
  • Business Quant data shows Tax Provisions for XFOR at -$30000.0 in Q3 2025, $37000.0 in Q2 2025, and $34000.0 in Q1 2025.